396 research outputs found
The origin of organic emission in NGC 2071
Context: The physical origin behind organic emission in embedded low-mass
star formation has been fiercely debated in the last two decades. A multitude
of scenarios have been proposed, from a hot corino to PDRs on cavity walls to
shock excitation.
Aims: The aim of this paper is to determine the location and the
corresponding physical conditions of the gas responsible for organics emission
lines. The outflows around the small protocluster NGC 2071 are an ideal testbed
to differentiate between various scenarios.
Methods: Using Herschel-HIFI and the SMA, observations of CH3OH, H2CO and
CH3CN emission lines over a wide range of excitation energies were obtained.
Comparisons to a grid of radiative transfer models provide constraints on the
physical conditions. Comparison to H2O line shape is able to trace gas-phase
synthesis versus a sputtered origin.
Results: Emission of organics originates in three spots: the continuum
sources IRS 1 ('B') and IRS 3 ('A') as well as a outflow position ('F').
Densities are above 10 cm and temperatures between 100 to 200 K.
CH3OH emission observed with HIFI originates in all three regions and cannot be
associated with a single region. Very little organic emission originates
outside of these regions.
Conclusions: Although the three regions are small (<1,500 AU), gas-phase
organics likely originate from sputtering of ices due to outflow activity. The
derived high densities (>10 cm) are likely a requirement for organic
molecules to survive from being destroyed by shock products. The lack of
spatially extended emission confirms that organic molecules cannot (re)form
through gas-phase synthesis, as opposed to H2O, which shows strong line wing
emission. The lack of CH3CN emission at 'F' is evidence for a different history
of ice processing due to the absence of a protostar at that location and recent
ice mantle evaporation.Comment: 10 Pages, 8 figures, Accepted for Astronomy and Astrophysic
Auras and the risk of seizures with impaired consciousness following epilepsy surgery: implications for driving
OBJECTIVE: To calculate the chance of a seizure in the next year (COSY) for seizures with impaired awareness in those experiencing auras only, those with no seizures and those with continuing seizures. Epilepsy surgery is an effective treatment for refractory focal epilepsy. Driving is an important factor affecting quality of life. In the UK, driving is not permitted if focal seizures with no impairment of awareness (auras, simple partial seizures) continue, if there is a prior history of seizures with impaired awareness, as will invariably be the case in those having epilepsy surgery. Current UK driving regulations allow driving if COSY is less than 20%. METHOD: We calculated COSY in 819 epilepsy surgery patients with up to 25 years follow-up. Each patient year was graded on the The International League against Epilepsy surgery outcome scale. RESULTS: Patients who were entirely seizure-free for 1, 2 and 3 years had COSY of 4.9%, 3.5% and 2.4% respectively. Patients with only auras within the last 1, 2 or 3 years had a COSY of 11.3%, 9.2% and 7.8% respectively. CONCLUSIONS: Individuals with auras only after epilepsy surgery had a higher COSY than those who were seizure-free. If a COSY of below 20% is regarded as an acceptable risk, it may be suggested that those with auras only in a given year be allowed to drive. The relative risk of these patients causing accidents is lower than population groups such as those aged 75 years, who are permitted to drive
Towards an Open Set of Real-World Benchmarks for Model Queries and Transformations
International audienceWith the growing size and complexity of systems under design, industry needs a generation of Model-Driven Engineering (MDE) tools, especially model query and transformation, with the proven capability to handle large-scale scenarios. While researchers are proposing several technical solutions in this sense, the community lacks a set of shared scalability benchmarks, that would simplify quantitative assessment of advancements and enable cross-evaluation of different proposals. Benchmarks in previous work have been synthesized to stress specific features of model management, lacking both generality and industrial validity. In this paper, we initiate an effort to define a set of shared benchmarks, gathering queries and transformations from real-world MDE case studies. We make these case available to community evaluation via a public MDE benchmark repository
Premature mortality in refractory partial epilepsy: does surgical treatment make a difference?
Background: Epilepsy carries an increased risk of premature death. For some people with intractable focal epilepsy, surgery offers hope for a seizure-free life. The authors aimed to see whether epilepsy surgery influenced mortality in people with intractable epilepsy. Methods: The authors audited survival status in two cohorts (those who had surgery and those who had presurgical assessment but did not have surgery). Results: There were 40 known deaths in the non-surgical group (3365 person years of follow-up) and 19 in the surgical group (3905 person-years of follow-up). Non-operated patients were 2.4 times (95% CI 1.4 to 4.2) as likely to die as those who had surgery. They were 4.5 times (95% CI 1.9 to 10.9) as likely to die a probable epilepsy-related death. In the surgical group, those with ongoing seizures 1 year after surgery were 4.0 (95% CI 1.2 to 13.7) times as likely to die as those who were seizure-free or who had only simple partial seizures. Time-dependent Cox analysis showed that the yearly outcome group did not significantly affect mortality (HR 1.3, 95% CI 0.9 to 1.8). Conclusion: Successful epilepsy surgery was associated with a reduced risk of premature mortality, compared with those with refractory focal epilepsy who did not have surgical treatment. To some extent, the reduced mortality is likely to be conferred by inducing freedom from seizures. It is not certain whether better survival is attributable only to surgery, as treatment decisions were not randomised, and there may be inherent differences between the groups.<br/
Hesitancy around low dose CT screening for lung cancer
Lung cancer is the leading cause of cancer death worldwide. The absence of symptoms in early stage (I/II) disease, when curative treatment is possible, results in greater than 70% of cases being diagnosed at late stage (III/IV), when treatment is rarely curative. This contributes greatly to lung cancer's poor prognosis which sees only 16.2% of individuals diagnosed with the disease alive at 5 years. Early detection is key to improving lung cancer survival outcomes. As a result, there has been longstanding interest in finding a reliable screening test. After little success with chest radiography and sputum cytology, in 2011 the US National Lung Screening Trial (NLST) demonstrated that annual Low Dose Computed Tomography (LDCT) screening reduced lung cancer specific mortality by 20%, when compared with annual chest radiography. In 2020, the NELSON study demonstrated an even greater reduction in lung cancer specific mortality for LDCT screening at 0, 1, 3 and 5.5 years of 24% in men, when compared to no screening. Despite these impressive results, a call to arms in the 2017 European position statement on Lung Cancer Screening (LCS), and the widespread introduction across the US, there was, until recently, no population-based European national screening programme in place. We address the potential barriers and outstanding concerns including common screening foes, such as false positive tests, overdiagnosis, and the negative psychological impact of screening, as well as others more unique to LDCT LCS, including appropriate risk stratification of potential participants, radiation exposure and incidental findings. In doing this, we conclude that whilst the evidence generated from ongoing work can be used to refine the screening process, for those risks which remain, appropriate and acceptable mitigations are available, and none should serve as barriers to the implementation of national unified LCS programmes across Europe and beyond
Reasons for not having epilepsy surgery
Objective: This study was undertaken to determine reasons for adults with drug-resistant focal epilepsy who undergo presurgical evaluation not proceeding with surgery, and to identify predictors of this course. //
Methods: We retrospectively analyzed data on 617 consecutive individuals evaluated for epilepsy surgery at a tertiary referral center between January 2015 and December 2019. We compared the characteristics of those in whom a decision not to proceed with surgical treatment was made with those who underwent definitive surgery in the same period. Multivariate logistic regression was performed to identify predictors of not proceeding with surgery. //
Results: A decision not to proceed with surgery was reached in 315 (51%) of 617 individuals evaluated. Common reasons for this were an inability to localize the epileptogenic zone (n = 104) and the presence of multifocal epilepsy (n = 74). An individual choice not to proceed with intracranial electroencephalography (icEEG; n = 50) or surgery (n = 39), risk of significant deficit (n = 33), declining noninvasive investigation (n = 12), and coexisting neurological comorbidity (n = 3) accounted for the remainder. Compared to 166 surgically treated patients, those who did not proceed to surgery were more likely to have a learning disability (odds ratio [OR] = 2.35, 95% confidence interval [CI] = 1.07‒5.16), normal magnetic resonance imaging (OR = 4.48, 95% CI = 1.68–11.94), extratemporal epilepsy (OR = 2.93, 95% CI = 1.82‒4.71), bilateral seizure onset zones (OR = 3.05, 95% CI = 1.41‒6.61) and to live in more deprived socioeconomic areas (median deprivation decile = 40%–50% vs. 50%–60%, p < .05). //
Significance: Approximately half of those evaluated for surgical treatment of drug-resistant focal epilepsy do not proceed to surgery. Early consideration and discussion of the likelihood of surgical suitability or need for icEEG may help direct referral for presurgical evaluation
Seizure outcomes in people with drug-resistant focal epilepsy evaluated for surgery but do not proceed
Objective: To ascertain seizure outcomes in people with drug-resistant focal epilepsy considered for epilepsy surgery but who did not proceed. // Methods: We identified people discussed at a weekly presurgical epilepsy multi-disciplinary (MDT) meeting from January 2015 to December 2019 and in whom a decision not to proceed to surgery was made. Seizure outcomes were obtained from individuals, primary care physicians and attending neurologists at a minimum of 12 months following the not to proceed decision. // Results: We considered 315 people who did not proceed to surgery after evaluation. Nine died, and 25 were lost to follow-up. We included 281 people with a median follow-up of 2.4 (IQR 1.5–4) years. In total, 83 (30%) people reported that seizures had improved or resolved since the MDT meeting. Thirteen (5%) were seizure-free over the last 12 months of follow-up, 70 (25%) had experienced more than 50% reduction in seizure frequency, 180 (64%) had no meaningful change, and 18 (6%) reported a doubling of seizure frequency. Of the 53 (16%) who had vagal nerve stimulation, 19/53 (37%) reported more than 50% reduction in frequency, including one seizure-free. // Significance: The chances of seizure freedom with further medications and neurostimulation are low for people with drug-resistant focal epilepsy who have been evaluated for surgery and do not proceed, but improvement may still occur. Up to a quarter have a > 50% reduction in seizures, and one in twenty become seizure-free eventually. Trying additional anti-seizure medication and neurostimulation is worthwhile in this population
High-throughput, automated quantification of white matter neurons in mild malformation of cortical development in epilepsy
Introduction
In epilepsy, the diagnosis of mild Malformation of Cortical Development type II (mMCD II) predominantly relies on the histopathological assessment of heterotopic neurons in the white matter. The exact diagnostic criteria for mMCD II are still ill-defined, mainly because findings from previous studies were contradictory due to small sample size, and the use of different stains and quantitative systems. Advance in technology leading to the development of whole slide imaging with high-throughput, automated quantitative analysis (WSA) may overcome these differences, and may provide objective, rapid, and reliable quantitation of white matter neurons in epilepsy. This study quantified the density of NeuN immunopositive neurons in the white matter of up to 142 epilepsy and control cases using WSA. Quantitative data from WSA was compared to two other systems, semi-automated quantitation, and the widely accepted method of stereology, to assess the reliability and quality of results from WSA.
Results
All quantitative systems showed a higher density of white matter neurons in epilepsy cases compared to controls (P = 0.002). We found that, in particular, WSA with user-defined region of interest (manual) was superior in terms of larger sampled size, ease of use, time consumption, and accuracy in region selection and cell recognition compared to other methods. Using results from WSA manual, we proposed a threshold value for the classification of mMCD II, where 78% of patients now classified with mMCD II were seizure-free at the second post-operatively follow up.
Conclusion
This study confirms the potential role of WSA in future quantitative diagnostic histology, especially for the histopathological diagnosis of mMCD
The validity of the Spelling and Grammar Waiver as a reasonable accommodation in Leaving Certificate examinations in Ireland
Analisi degli infortuni lavoro correlati a fini di prevenzione: un approccio evoluto di indagine sulla catena degli eventi
- …